KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Masatoshi Kudo(Kindai University), Ann‐Lii Cheng(National Taiwan University), Olivier Rosmorduc(Assistance Publique – Hôpitaux de Paris), Daniel H. Palmer(University of Liverpool), Gontran Verset, Vittorina Zagonel(Istituto Oncologico Veneto), Stephen L. Chan(Chinese University of Hong Kong), Bruno Daniele(Azienda Ospedaliera G.Rummo), Jennifer J. Knox(National Cancer Center), Julien Edeline(Inserm), Richard S. Finn(University of California, Los Angeles), Arndt Vogel(Princess Margaret Cancer Centre), Debashis Sarker(King's College - North Carolina), Sadahisa Ogasawara(Chiba University), Junshui Ma(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stéphane Cattan(Université Lille Nord de France), Chris Verslype(Universitair Ziekenhuis Leuven), Abby B. Siegel(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 37
Related Papers
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2021|6.6k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k